ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.

H.-P. Chang,1 C.-Y. Lee,2 C.-C. Si,1 M.-K. Tsai,2 F.-L. Lin Wu.1,3

1Graduate Institute of Clinical Pharmacy, National Taiwan University, College of Medicine, Taipei, Taiwan
2Surgery, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.

Meeting: 2016 American Transplant Congress

Abstract number: B118

Keywords: Drug interaction, Immunosuppression, Kidney transplantation

Session Information

Session Name: Poster Session B: Drug Minimization

Session Type: Poster Session

Date: Sunday, June 12, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Studies on the effect of everolimus on tacrolimus pharmacokinetics (PK) were limited and the results were inconsistent. In contrast, studies showed there was little effect of mycophenolate mofetil (MMF) on tacrolimus PK. This study investigated the influence of everolimus on tacrolimus PK, using MMF-tacrolimus combination as a control.

This was a prospective, randomized, open-label study. De novo renal transplant recipients aged 20-65 years were included. Exclusion criteria were pregnancy, retransplantation or multiorgan transplantation, positive for human immunodeficiency virus, hepatitis B or C virus, aminotransferase level higher than two times the upper limit of normal, and history of rheumatoid arthritis. Patients were randomized to receive either everolimus (1 mg bid) or MMF (10-15 mg/kg bid) in combination with tacrolimus and corticosteroids. Doses of tacrolimus were adjusted to maintain trough concentration (Ctrough) in the range of 8-12 ng/mL. Steady-state PK profiles of tacrolimus and everolimus using whole blood sample were analyzed predose and 1, 2, 3, 5, 8, 12 hours postdose. PK parameters were analyzed by noncompartmental method. Continuous variables and categorical variables were analyzed by unpaired two-tailed t test and Fisher's exact test, respectively.

Twelve patients completed the study, with six in each group. There were no significant differences in patient demographic between two groups. Tacrolimus doses required to maintain the same target Ctrough were two times higher in everolimus-treated patients than in those treated with MMF (5.0 ± 1.3 vs. 2.5 ± 0.7 mg bid; P = 0.002). Dose-normalized tacrolimus area under the curve (AUC0-12) (29.00 ± 6.22 vs. 55.14 ± 17.32 hr*ng/mL/mg, P = 0.012), dose-normalized tacrolimus Ctrough (1.23 ± 0.32 vs. 3.13 ± 1.15 ng/mL/mg, P = 0.009), and dose-normalized tacrolimus peak concentration (Cmax) (5.32 ± 1.31 vs. 8.48 ± 1.85 ng/mL/mg, P = 0.009) were significantly lower in patients who received everolimus than in those who received MMF.

In conclusion, tacrolimus exposure was significantly lower in everolimus-treated patients than those treated with MMF after kidney transplant. Tacrolimus doses should be adjusted, and Ctrough should be closely monitored when switch between everolimus and MMF combination.

CITATION INFORMATION: Chang H.-P, Lee C.-Y, Si C.-C, Tsai M.-K, Lin Wu F.-L. Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Chang H-P, Lee C-Y, Si C-C, Tsai M-K, Wu F-LLin. Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/significant-pharmacokinetic-interaction-between-everolimus-and-tacrolimus-in-de-novo-renal-transplant-recipients/. Accessed May 31, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences